Abnormal Sodium and Chlorine Level Is Associated With Prognosis of Lung Cancer Patients
暂无分享,去创建一个
[1] Lei Wu,et al. Pretreatment Low Serum Sodium as a Prognostic Factor for Patients with Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy , 2022, Journal of oncology.
[2] A. Awasthi,et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity , 2021, Science advances.
[3] F. Tan,et al. Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study , 2021, Cancer medicine.
[4] J. Rathmell,et al. Ex Vivo High Salt Activated Tumor-Primed CD4+T Lymphocytes Exert a Potent Anti-Cancer Response , 2021, Cancers.
[5] N. Aggerholm-Pedersen,et al. Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study. , 2021, Lung cancer.
[6] Junfeng Zhang,et al. High-salt diet inhibits tumour growth in mice via regulating myeloid-derived suppressor cell differentiation , 2020, Nature Communications.
[7] I. Asangani,et al. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression , 2020, Cell.
[8] J. Shim,et al. Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study , 2020, BMC Palliative Care.
[9] A. Peri,et al. Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro , 2019, Endocrine.
[10] T. Wurdinger,et al. Tumor-educated platelets. , 2019, Blood.
[11] N. Beerenwinkel,et al. Neutrophils escort circulating tumour cells to enable cell cycle progression , 2019, Nature.
[12] Min K. Tsai,et al. An Lkb1-Sik axis suppresses lung tumor growth and controls differentiation. , 2019, Cancer discovery.
[13] S. Kannan,et al. Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy , 2018, Journal of Cancer Research and Therapeutics.
[14] W. Jochum,et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.
[15] Frank C. Detterbeck,et al. The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.
[16] T. Dubose,et al. Hyponatremia in the cancer patient. , 1993, Oncology.